Skip to content

Neuropace, Inc. NPCE Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Medtronic logo
MedtronicMDT
LivaNova logo
LivaNovaLIVN
ClearPoint Neuro logo
ClearPoint NeuroCLPT
Inspire Medical Systems logo
Inspire Medical SystemsINSP
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP

Other financials

Income statement

See full
Revenue$22.1M-2.0%
Gross profit$18.0M+4.1%
Operating income-$5.6M-8.2%
Net income-$6.7M-1.5%
EPS (diluted)-$0.20+4.8%

Balance sheet

See full
Cash & equivalents$15.6M-42.4%
Total debt$70.5M-3.7%
Total equity$14.5M-40.4%
Total assets$98.9M-10.3%

Cash flow

See full
Operating cash flow-$5.9M+21.1%
CapEx$117.0K+216%
Free cash flow-$6.0M+20.0%

Valuation

See full
Market cap$557.77M+63.4%
Enterprise value$612.6M+58.1%
P/S5.6×+1.6×

Profitability

See full
Gross margin78.3%+3.5pp
Operating margin-16.8%-3.5pp
Net margin-21.7%-4.5pp
FCF margin-10.3%-3.5pp

Returns & leverage

See full
Return on equity-111.4%-13.1pp
Debt / equity4.9×+1.9×
Current ratio5.4×-1.2×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuropace, Inc.'s deferred tax assets and other non-current assets?
Neuropace, Inc. (NPCE) reported deferred tax assets and other non-current assets of $106K in Q1 2026.
How has Neuropace, Inc.'s deferred tax assets and other non-current assets changed year-over-year?
Neuropace, Inc.'s deferred tax assets and other non-current assets increased by 606.7% year-over-year, from $15K to $106K.
What is the long-term trend for Neuropace, Inc.'s deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Neuropace, Inc.'s deferred tax assets and other non-current assets has grown at a 63.3% compound annual growth rate (CAGR), from $146K to $1.7M.